DK1485483T3 - Proteolyseresistent aktivt VEGF - Google Patents

Proteolyseresistent aktivt VEGF

Info

Publication number
DK1485483T3
DK1485483T3 DK03720320T DK03720320T DK1485483T3 DK 1485483 T3 DK1485483 T3 DK 1485483T3 DK 03720320 T DK03720320 T DK 03720320T DK 03720320 T DK03720320 T DK 03720320T DK 1485483 T3 DK1485483 T3 DK 1485483T3
Authority
DK
Denmark
Prior art keywords
vegf
nucleic acids
resistant active
active vegf
proteolysis resistant
Prior art date
Application number
DK03720320T
Other languages
Danish (da)
English (en)
Inventor
Sabine Eming
Thomas Krieg
Stephan Sollberg
Gereon Lauer
Original Assignee
Bayer Innovation Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Innovation Gmbh filed Critical Bayer Innovation Gmbh
Application granted granted Critical
Publication of DK1485483T3 publication Critical patent/DK1485483T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK03720320T 2002-03-08 2003-03-06 Proteolyseresistent aktivt VEGF DK1485483T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02005186A EP1342783A1 (de) 2002-03-08 2002-03-08 Proteolyseresistenter aktiver VEGF
PCT/EP2003/002289 WO2003076625A1 (de) 2002-03-08 2003-03-06 Proteolyseresistenter aktiver vegf

Publications (1)

Publication Number Publication Date
DK1485483T3 true DK1485483T3 (da) 2009-01-05

Family

ID=27741149

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03720320T DK1485483T3 (da) 2002-03-08 2003-03-06 Proteolyseresistent aktivt VEGF

Country Status (10)

Country Link
US (3) US7491696B2 (pt)
EP (2) EP1342783A1 (pt)
AT (1) ATE409230T1 (pt)
AU (1) AU2003223956A1 (pt)
CA (1) CA2518248A1 (pt)
DE (1) DE50310541D1 (pt)
DK (1) DK1485483T3 (pt)
ES (1) ES2312767T3 (pt)
PT (1) PT1485483E (pt)
WO (1) WO2003076625A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646697B (zh) * 2016-04-08 2019-03-19 新乡医学院 VEGF165b突变体及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor

Also Published As

Publication number Publication date
ATE409230T1 (de) 2008-10-15
DE50310541D1 (de) 2008-11-06
US20120258915A1 (en) 2012-10-11
WO2003076625A1 (de) 2003-09-18
EP1342783A1 (de) 2003-09-10
US20110009316A1 (en) 2011-01-13
CA2518248A1 (en) 2003-09-18
AU2003223956A1 (en) 2003-09-22
ES2312767T3 (es) 2009-03-01
US8168590B2 (en) 2012-05-01
US7491696B2 (en) 2009-02-17
EP1485483A1 (de) 2004-12-15
PT1485483E (pt) 2008-12-03
US20060148687A1 (en) 2006-07-06
EP1485483B1 (de) 2008-09-24

Similar Documents

Publication Publication Date Title
ITTO20011228A0 (it) Contenitore per ago monouso.
ATE462006T1 (de) Isoform des vegfs
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
DE60111570D1 (de) Isoindolin-1-on als glukokinaseaktivatoren
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
MX353234B (es) Variantes de polipeptidos con función efectora alterada.
DE69916591T2 (de) Hochzähe, hochfeste amorphe zirkoniumlegierung
DE69907137D1 (de) Autoklavierbare pharmazeutische zusammensetzungen mit komplexbildner
CY1108446T1 (el) Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας
DE50207315D1 (de) Verschlusskappe für infusions- oder transfusionsflaschen
ATE353336T1 (de) Neues peptid mit angiotensinkonvertase hemmender wirkung
DE60200078D1 (de) Infusionsbehälter
DE50206480D1 (de) Antimikrobiell wirkendes peptid
UY28344A1 (es) Nuevos compuestos
AR047756A1 (es) Composicion liquida biologicamente estable de fviii, de fvw o del complejo fviii/fvw humanos
DK1485483T3 (da) Proteolyseresistent aktivt VEGF
DK1343896T3 (da) Lille syreoplöseligt sporeprotein og anvendelser deraf
FI20011550A0 (fi) Polypeptidien immobilisointimenetelmä
DK1390364T3 (da) Aryl-8-azabicyclo[3.2.1]octaner til behandling af depression
DE60040668D1 (de) Antibakterielles protein chlamysin-b, dafür kodierendes gen und ein expresionssystem dafür
ITTO20020743A1 (it) Procedimento per la lavorazione di uno stampo in resina.
ES1048112Y (es) Recipiente refrigerado.
IT1317507B1 (it) Dispositivo per l'applicazione di cravatte, particolarmente perfacilitare la realizzazione del nodo della cravatta.
IT1299188B1 (it) Plasmide per la produzione di peptidi antimicrobici in batteri ricombinanti.